WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Sandra E. Poole as Senior Vice President, Technical Operations. Ms. Poole brings to ImmunoGen more than 25 years of experience related to the development and manufacturing of innovative biopharmaceuticals, most recently as the senior vice president of biologics manufacturing at Genzyme. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.
"She brings extensive experience successfully leading complex biologics operations, integrating functions that include process development, production, and quality assurance."
"Sandra joins ImmunoGen in a newly established position that reflects our advancing, broadening pipeline and escalating preparations for later-stage clinical trials," commented Mr. Junius. "She brings extensive experience successfully leading complex biologics operations, integrating functions that include process development, production, and quality assurance."
Prior to ImmunoGen, Ms. Poole had a 15-year career with Genzyme that spanned a wealth of bio-manufacturing-related functions with increasing responsibility, including heading up technology development, overseeing the construction, start-up, tech transfer and approval of a fully integrated manufacturing operation in Belgium and, most recently, leading Genzyme's global network of biologic manufacturing sites.
Prior to joining Genzyme in 1999, Ms. Poole oversaw process development and played a key role in establishing technical operations at Canadian-based Biomira, Inc. She holds both a Master and a Bachelor of Applied Science degree from the University of Waterloo (Canada) in chemical engineering and also completed the executive program in business management at the Massachusetts Institute of Technology Sloan School of Management.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
Carol Hausner, 781-895-0600
Pure Communications, Inc.
Dan Budwick, 973-271-6085